Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight
The squamous cell carcinoma (SCC) market is experiencing robust growth, driven predominantly by the increasing incidence of the disease. Over the past few decades, we have observed a significant rise in SCC cases, which can be attributed to heightened exposure to ultraviolet (UV) radiation. Key risk factors include increased sun exposure and the use of tanning beds. Furthermore, the market is poised for further expansion due to advancements in treatment options. The development of new drugs and therapies is expected to play a crucial role in propelling market growth, offering more effective and diverse solutions for SCC patients.
New York, USA, Sept. 20, 2024 (GLOBE NEWSWIRE) — Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight
The squamous cell carcinoma (SCC) market is experiencing robust growth, driven predominantly by the increasing incidence of the disease. Over the past few decades, we have observed a significant rise in SCC cases, which can be attributed to heightened exposure to ultraviolet (UV) radiation. Key risk factors include increased sun exposure and the use of tanning beds. Furthermore, the market is poised for further expansion due to advancements in treatment options. The development of new drugs and therapies is expected to play a crucial role in propelling market growth, offering more effective and diverse solutions for SCC patients.
DelveInsight’s ‘Squamous Cell Carcinoma Pipeline Insight 2024‘ report provides comprehensive global coverage of pipeline squamous cell carcinoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the squamous cell carcinoma pipeline domain.
Key Takeaways from the Squamous Cell Carcinoma Pipeline Report
- DelveInsight’s squamous cell carcinoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for squamous cell carcinoma treatment.
- Key squamous cell carcinoma companies such as Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, PureTech Health, Rakuten Medical, Jacobio Pharmaceuticals, and others are evaluating new squamous cell carcinoma drugs to improve the treatment landscape.
- Promising squamous cell carcinoma pipeline therapies such as HB-200, ZEN003694, HFB-301001, NBTXR-3, GSK-4057190, Olaparib, VCN-01, mRNA-4157, XL092, Vobramitamab duocarmazine, VB10.NEO, TTX-080, TOS-358, TBio-4101, RG6058, MCLA-158, LYT-200, ASP-1929, JAB-3312, and others are under different phases of squamous cell carcinoma clinical trials.
- In July 2024, BioAtla announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track Designation (FTD) to ozuriftamab vedotin, the Company’s conditionally and reversibly active ROR2 antibody-drug conjugate directed for the treatment of patients with recurrent or metastatic SCCHN with disease progression on or after platinum-based chemotherapy and anti-PD-1/L1 antibody therapy.
- In June 2024, Tuhura Biosciences and Kintara Therapeutics announced positive results from the primary analysis of TuHURA’s completed Phase Ib trial evaluating IFx-2.0 among patients with advanced or metastatic MCC or cSCC who exhibited primary resistance to immune checkpoint inhibitor (ICIs) therapy.
- In June 2024, Moderna and Merck announced the first presentation of results from a planned analysis from the Phase IIb randomized KEYNOTE-942/mRNA-4157-P201 study.
- In June 2024, Genmab announced data from the Phase II innovaTV 207 trial (NCT03485209) Part C (n=40), investigating tisotumab vedotin, an antibody-drug conjugate directed to tissue factor, demonstrated encouraging antitumor activity as a monotherapy in patients with head and neck squamous cell carcinoma (HNSCC) who experienced disease progression on or after first-line therapy.
- In April 2024, the FDA granted fast-track designation to the IgG4 monoclonal antibody LYT-200 in combination with a PD-1 inhibitor for the treatment of patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC).
- In May 2024, Rakuten Medical announced the updated safety and efficacy findings from an interim evaluation of an open-label Phase Ib/II study ASP-1929 of photoimmunotherapy using ASP-1929 in combination with anti-PD-1 for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC).
- In December 2023, Exelixis announced the initiation of STELLAR-305, a phase II/III pivotal trial evaluating zanzalintinib in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Request a sample and discover the recent advances in squamous cell carcinoma treatment drugs @ Squamous Cell Carcinoma Pipeline Report
The squamous cell carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage squamous cell carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the squamous cell carcinoma clinical trial landscape.
Squamous Cell Carcinoma Overview
Squamous cell carcinoma (SCC) is a type of skin cancer originating from the squamous cells in the epidermis, the skin’s outermost layer. It is the second most common skin cancer, making up about 20% of all cases. SCC is known for its aggressive nature, high potential for metastasis, and poor survival rates. The primary risk factor for SCC is prolonged exposure to ultraviolet radiation, especially during childhood and youth. Other contributing factors include immunosuppression, chronic inflammation, and genetic mutations such as those in the p53 gene.
Common symptoms of SCC include rough, reddish, scaly patches on the skin, often with raised borders. These patches may also present as open sores or brown spots resembling age spots. SCC can also appear as firm, dome-shaped growths, wart-like growths, or small horn-like protrusions. It can develop in sun-exposed areas and less commonly exposed areas like the palms, soles, or genital regions. Symptoms may also include itching, soreness, or numbness in the affected area.
The treatment and management of SCC, particularly in the lungs, head, and neck, require a multidisciplinary approach tailored to the cancer’s specific characteristics. For lung SCC, treatment usually involves surgery followed by chemotherapy, with lobectomy preferred for stage II tumors. Sub-lobar resection might be considered when surgery is not feasible. For metastatic or recurrent head and neck SCC, chemotherapy options are available. Treatment options for head and neck SCC include surgery, radiation therapy, chemotherapy, and targeted therapy, either individually or in combination, depending on the cancer’s stage and location. Treatment planning focuses on preserving function and quality of life, minimizing side effects, and achieving the best possible outcomes. Close monitoring and follow-up are crucial for optimal results and timely management of potential complications.
Find out more about squamous cell carcinoma treatment drugs @ Drugs for Squamous Cell Carcinoma Treatment
A snapshot of the Squamous Cell Carcinoma Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| NBTXR-3 | Nanobiotix | Phase III | Free radical stimulants | Intratumoral |
| mRNA-4157 | Moderna Therapeutics | Phase II/III | Immunostimulants | Intramuscular |
| HB-200 | Hookipa Pharma | Phase II | Immunostimulants | Intravenous |
| MCLA-158 | Merus | Phase III | Antibody-dependent cell cytotoxicity; Epidermal growth factor receptor antagonists | Intravenous |
| HFB-301001 | HiFiBiO | Phase I | Intravenous |
Learn more about the emerging squamous cell carcinoma pipeline therapies @ Squamous Cell Carcinoma Clinical Trials
Squamous Cell Carcinoma Therapeutics Assessment
The squamous cell carcinoma pipeline report proffers an integral view of the Squamous Cell Carcinoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Squamous Cell Carcinoma Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Intravenous, Subcutaneous, Oral, Intramuscular
- Therapeutics Assessment By Molecule Type: Monoclonal antibody, Small molecule, Peptide
- Therapeutics Assessment By Mechanism of Action: Free radical stimulants, Immunostimulants, Antibody-dependent cell cytotoxicity, Epidermal growth factor receptor antagonists,
- Key Squamous Cell Carcinoma Companies: Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, PureTech Health, Rakuten Medical, Jacobio Pharmaceuticals, and others
- Key Squamous Cell Carcinoma Pipeline Therapies: HB-200, ZEN003694, HFB-301001, NBTXR-3, GSK-4057190, Olaparib, VCN-01, mRNA-4157, XL092, Vobramitamab duocarmazine, VB10.NEO, TTX-080, TOS-358, TBio-4101, RG6058, MCLA-158, LYT-200, ASP-1929, JAB-3312, and others
Dive deep into rich insights for new drugs for squamous cell carcinoma treatment, visit @ Squamous Cell Carcinoma Drugs
Table of Contents
| 1. | Squamous Cell Carcinoma Pipeline Report Introduction |
| 2. | Squamous Cell Carcinoma Pipeline Report Executive Summary |
| 3. | Squamous Cell Carcinoma Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Squamous Cell Carcinoma Clinical Trial Therapeutics |
| 6. | Squamous Cell Carcinoma Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Squamous Cell Carcinoma Pipeline: Late-Stage Products (Phase III) |
| 8. | Squamous Cell Carcinoma Pipeline: Mid-Stage Products (Phase II) |
| 9. | Squamous Cell Carcinoma Pipeline: Early-Stage Products (Phase I) |
| 10. | Squamous Cell Carcinoma Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Squamous Cell Carcinoma Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Squamous Cell Carcinoma Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the squamous cell carcinoma pipeline therapeutics, reach out @ Squamous Cell Carcinoma Treatment Drugs
Related Reports
Cutaneous Squamous Cell Carcinoma Pipeline
Cutaneous Squamous Cell Carcinoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cutaneous squamous cell carcinoma companies, including Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, among others.
Cutaneous Squamous Cell Carcinoma Market
Cutaneous Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cutaneous squamous cell carcinoma companies, including Genentech, Inc., Incyte Corporation, Boehringer Ingelheim, Merck Sharp & Dohme LLC, Phio Pharmaceuticals Inc., Rakuten Medical, Inc., Shimadzu Corporation, Regeneron Pharmaceuticals, Sanofi, Morphogenesis, Inc., Sirnaomics, NeoImmuneTech, SOTIO Biotech AG, among others.
Metastatic Cutaneous Squamous Cell Carcinoma Market
Metastatic Cutaneous Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic cutaneous squamous cell carcinoma companies, including NFlection Therapeutics, SpringWorks Therapeutics, Shanghai Fosun Pharmaceutical Development Co, Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis, Array BioPharma, among others.
Basal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key basal cell carcinoma companies, including AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, among others.
Esophageal Squamous Carcinoma Market
Esophageal Squamous Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key esophageal squamous carcinoma companies, including BeiGene, AstraZeneca, Ipsen, Shire, Sanofi, Seagen, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com
